CDK2 and breast carcinoma: Based on the reported PK inhibitory activity of isatin and benzofuran nuclei, specially, on the homologous CDK2 and GSK-3β kinases, a hybridisation strategy of these two privileged scaffolds was adapted to design dual CDK2/GSK-3β hybrid inhibitors which could target breast cancer.